- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03105804
CSD170301: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Four Different Electronic Cigarettes
April 9, 2018 updated by: RAI Services Company
CSD170301: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes
To determine the rate and amount of nicotine uptake with 10-minute ad libitum use of four different marketed electronic cigarettes.
Furthermore, to measure overall product liking by subjects to assess potential willingness to seek out the Electronic Cigarette (EC) again in the future.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This will be a single-center, randomized, open-label, parallel study during which up to 140 healthy adult subjects, consisting of 35 subjects per marketed EC product, will be enrolled.
Subjects will be evaluated for plasma nicotine uptake, as well as overall product liking.
The study will involve the use of four (4) marketed EC products in tobacco consumers who are exclusive smokers (i.e., naïve EC users) or dual users of cigarettes and ECs (i.e., intermittent EC users).
Study Type
Interventional
Enrollment (Actual)
144
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Neptune, New Jersey, United States, 07753
- Inflamax Research, Inc.
-
-
North Carolina
-
High Point, North Carolina, United States, 27265
- High Point Clinical Trials Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to read, understand, and willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English.
- Generally healthy males and females, 21 to 60 years of age, inclusive, at Screening Visit.
Subjects must meet one (a or b) of the following tobacco use conditions:
- Exclusive cigarette smoker who self-reports smoking at least (≥) 10 cigarettes per day for at least 6 months prior to Screening Visit. Brief periods of abstinence more than 30 days prior to Screening due to illness, quit attempt or clinical study participation will be allowed at the discretion of the Investigator.
- Dual user of combustible cigarettes and ECs who self-reports: 1. Smoking at least (≥) 10 cigarettes per day for at least 6 months prior to Screening Visit. Brief periods of abstinence more than 30 days prior to Screening due to illness, quit attempt or clinical study participation will be allowed at the discretion of the Investigator and 2. Using a nicotine-containing cig-a-like EC or a tank system EC either daily or at least weekly for at least 3 months prior to Screening Visit.
- Willing to be confined overnight and abstain from tobacco- and nicotine- containing product use for 12 hours prior to IP use through Study Discharge.
- Willing to use assigned IP during the study according to protocol.
- Expired breath carbon monoxide (ECO) level is ≥10 parts per million (ppm) at the Screening Visit and Study Day 1.
- Positive urine cotinine test at the Screening Visit and Study Day 1.
- No intent to quit smoking or vaping from Screening to Study Day 2.
- Females of childbearing age must be willing to use a form of contraception acceptable to the Investigator from the time of signing informed consent until Study Discharge, or be surgically sterile for at least 90 days prior to the Screening Visit.
Exclusion Criteria:
- Presence of clinically significant or unstable/uncontrolled acute or chronic medical conditions at the Screening Visit, as determined by the Investigator, that would preclude a subject from participating safely in the study (e.g., uncontrolled hypertension, diabetes, asthma or other lung disease, cardiac disease, neurological disease or psychiatric disorders) based on safety assessments such as clinical laboratory tests, pregnancy tests, medical history, and physical/oral examinations.
- At risk for heart disease, as determined by the Investigator.
- Systolic blood pressure of ≥150 mmHg or a diastolic blood pressure of ≥ 95 mmHg, measured after being seated for 5 minutes.
- Weight of ≤ 110 pounds.
- Poor peripheral venous access.
- Use of medicine for treatment of depression or asthma (e.g., paroxetine [Paxil®], montelukast [Singulair®], albuterol [Proventil® HFA]), as deemed clinically significant by the Investigator.
- Use of any medication or substance that aids in smoking cessation, including but not limited to any nicotine replacement therapy (NRT) (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within 30 days prior to the Screening Visit.
- History or presence of hemophilia or other bleeding disorders.
- History or presence of clotting disorders with concomitant use of anticoagulants (e.g., clopidogrel [Plavix®], warfarin [Coumadin®, Jantoven®] and aspirin [> 325 mg/day]).
- Participation in another clinical trial within (≤) 30 days prior to the time of consent. The 30-day window for each subject will be derived from the date of the last study event in the previous study to the time of consent of the current study.
- Positive test for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus antibody (anti-HCV).
- Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.
- Females ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.
- A positive urine drug screen without disclosure of corresponding concomitant medication(s) at the Screening Visit or on Study Day 1.
- A positive alcohol breathalyzer result at Screening Visit or on Study Day 1.
- Employed by a tobacco or nicotine company, the study site, or handles tobacco or nicotine-containing products as part of their job.
- Determined by the Investigator to be inappropriate for the study, including a subject who is unable to communicate or unwilling to cooperate with the clinical staff.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FT21039 Group
7 day at-home use of electronic cigarette FT21039 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
Experimental: FT21041 Group
7 day at-home use of electronic cigarette FT21041 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
Experimental: FT21044 Group
7 day at-home use of electronic cigarette FT21044 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
Experimental: FT21042 Group
7 day at-home use of electronic cigarette FT21042 followed by a 2 day in-clinic period.
|
An electronic cigarette
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax (Maximum baseline-adjusted nicotine plasma concentration)
Time Frame: -5, -0.5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 Minutes
|
To assess nicotine uptake with the start of a 10-minute ad libitum Investigational Product (IP) use period.
|
-5, -0.5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 Minutes
|
AUCnic0-60
Time Frame: -5, -0.5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 Minutes
|
Area under the baseline-adjusted nicotine concentration-versus-time curve from time zero to 60 minutes after the start of a 10-minute ad libitum IP use period.
|
-5, -0.5, 3, 5, 8, 10, 11, 12, 15, 20, 30, 60 Minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax and AUCnic0-15
Time Frame: -5, -0.5, 3, 5, 8, 10, 12, 15 Minutes
|
Maximum baseline-adjusted plasma nicotine concentration and area under the baseline-adjusted nicotine concentration-versus-time curve from time zero to 15 minutes after the start of IP use.
|
-5, -0.5, 3, 5, 8, 10, 12, 15 Minutes
|
PLoverall
Time Frame: 13 Minutes
|
Overall product liking (PL) is an additional measure of how much the subject likes the product, and is indicative of their potential willingness to seek out use of the product again at a later point in time; measured 13 minutes after the start of IP use.
|
13 Minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Frank Lee, MD, Inflamax Research Incorporated
- Principal Investigator: Margarita Nunez, MD, High Point Clinical Trial Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 29, 2017
Primary Completion (Actual)
October 27, 2017
Study Completion (Actual)
October 27, 2017
Study Registration Dates
First Submitted
April 4, 2017
First Submitted That Met QC Criteria
April 4, 2017
First Posted (Actual)
April 10, 2017
Study Record Updates
Last Update Posted (Actual)
April 10, 2018
Last Update Submitted That Met QC Criteria
April 9, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- CSD170301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
Columbia UniversityNational Cancer Institute (NCI)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking BehaviorsUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Maastricht University Medical CenterThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Medical University of South CarolinaRecruitingSmoking | Smoking Cessation | Tobacco Smoking | Cigarette SmokingUnited States
-
Ghana Health ServicesKwame Nkrumah University of Science and TechnologyNot yet recruitingSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking Behaviors
Clinical Trials on FT21039
-
RAI Services CompanyVince & Associates Clinical Research, Inc.Completed